Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference

Rhea-AI Summary

Stoke Therapeutics (Nasdaq: STOK) is set to present at the Cantor Global Healthcare Virtual Conference on September 28, 2021, at 4:00 p.m. ET. Chief Medical Officer Barry Ticho, M.D., Ph.D., will lead the session in a fireside chat format, which will be accessible via live audio webcast on the company's website. Stoke is a biotechnology firm focused on RNA-based medicines to treat severe diseases caused by protein expression deficiencies, including its lead candidate, STK-001, for Dravet syndrome and potential therapies for autosomal dominant optic atrophy.

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Medical Officer Barry Ticho, M.D., Ph.D., will present at the Cantor Global Healthcare Virtual Conference on Tuesday, September 28, 2021, at 4:00 p.m. ET.

A live audio webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/. A replay of the webcast will be available for 30 days following the fireside chat.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the Company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The Company’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The Company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the Company’s belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the Company on Twitter at @StokeTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005948/en/

Stoke Investor Contact:

Eric Rojas

Vice President, Investor Relations

IR@stoketherapeutics.com

617-312-2754

Source: Stoke Therapeutics, Inc.

FAQ

When is Stoke Therapeutics' presentation at the Cantor Global Healthcare Virtual Conference?

Stoke Therapeutics will present on September 28, 2021, at 4:00 p.m. ET.

Who is presenting for Stoke Therapeutics at the conference?

Dr. Barry Ticho, Chief Medical Officer of Stoke Therapeutics, will present.

How can I access the Stoke Therapeutics conference presentation?

The presentation will be available via live audio webcast on the Stoke Therapeutics website.

What is the focus of Stoke Therapeutics?

Stoke Therapeutics focuses on RNA-based medicines to address severe diseases by up-regulating protein expression.

What is STK-001 and its significance for Stoke Therapeutics?

STK-001 is Stoke's lead candidate in clinical testing for Dravet syndrome, a severe genetic epilepsy.